PURPOSE: The objective of this study was to evaluate breast carcinomas for the expression of cyclooxygenase-2 (Cox-2) using a tissue microarray (TMA) and to determine its clinical and prognostic relevance. METHODS: We analyzed Cox-2 expression in 600 samples from 200 breast carcinomas immunohistochemically performing TMA technology and semiquantitative analysis. Results were correlated with various clinicopathological variables and follow-up data. Expression of estrogen receptor, progesterone receptor, Ki-67, and Her-2/neu-oncogene was analyzed and correlated with Cox-2 status. RESULTS: We observed a moderate or strong cytoplasmic staining for Cox-2 in 78 (40.6%) of breast carcinomas. Increased Cox-2 expression corresponded to higher pT stage ( P=0.038), amplification of Her-2/neu ( P=0.032), lymphovascular invasion ( P=0.006), a high MIB-1 labeling index (LI) ( P<0.001), and histological grading ( P=0.013). We also observed an inverse relationship between strong Cox-2 expression and estrogen and progesterone receptor content of tumors ( P=0.037 and P=0.010). However, we could not demonstrate a significant association between Cox-2 staining and overall survival or disease free survival time. CONCLUSIONS: These results suggest that Cox-2 expression is significantly associated with less differentiated and more aggressive breast carcinomas and might therefore be a useful prognostic indicator as well as a target for therapy.
PURPOSE: The objective of this study was to evaluate breast carcinomas for the expression of cyclooxygenase-2 (Cox-2) using a tissue microarray (TMA) and to determine its clinical and prognostic relevance. METHODS: We analyzed Cox-2 expression in 600 samples from 200 breast carcinomas immunohistochemically performing TMA technology and semiquantitative analysis. Results were correlated with various clinicopathological variables and follow-up data. Expression of estrogen receptor, progesterone receptor, Ki-67, and Her-2/neu-oncogene was analyzed and correlated with Cox-2 status. RESULTS: We observed a moderate or strong cytoplasmic staining for Cox-2 in 78 (40.6%) of breast carcinomas. Increased Cox-2 expression corresponded to higher pT stage ( P=0.038), amplification of Her-2/neu ( P=0.032), lymphovascular invasion ( P=0.006), a high MIB-1 labeling index (LI) ( P<0.001), and histological grading ( P=0.013). We also observed an inverse relationship between strong Cox-2 expression and estrogen and progesterone receptor content of tumors ( P=0.037 and P=0.010). However, we could not demonstrate a significant association between Cox-2 staining and overall survival or disease free survival time. CONCLUSIONS: These results suggest that Cox-2 expression is significantly associated with less differentiated and more aggressive breast carcinomas and might therefore be a useful prognostic indicator as well as a target for therapy.
Authors: Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: Katharine Kirkpatrick; William Ogunkolade; A Elkak; Stephen Bustin; Paul Jenkins; Margaret Ghilchik; Kefah Mokbel Journal: Curr Med Res Opin Date: 2002 Impact factor: 2.580
Authors: Michelle D Holmes; Wendy Y Chen; Stuart J Schnitt; Laura Collins; Graham A Colditz; Susan E Hankinson; Rulla M Tamimi Journal: Breast Cancer Res Treat Date: 2011-07-05 Impact factor: 4.872
Authors: P Cejas; M A García-Cabezas; E Casado; J Barriuso; J A Fresno; E Díaz; C Belda-Iniesta; J Castro; E Espinosa; P Zamora; J Feliu; A Redondo; D A Hardisson; M González-Barón Journal: Clin Transl Oncol Date: 2005-07 Impact factor: 3.405
Authors: Thomas I Barron; Evelyn M Flahavan; Linda Sharp; Kathleen Bennett; Kala Visvanathan Journal: Cancer Res Date: 2014-08-01 Impact factor: 12.701
Authors: Kailash Mosalpuria; Carolyn Hall; Savitri Krishnamurthy; Ashutosh Lodhi; D Michael Hallman; Mary S Baraniuk; Anirban Bhattacharyya; Anthony Lucci Journal: Mol Clin Oncol Date: 2014-06-23
Authors: Powel H Brown; Kotha Subbaramaiah; Amoi P Salmon; Rebecca Baker; Robert A Newman; Peiying Yang; Xi Kathy Zhou; Reid P Bissonnette; Andrew J Dannenberg; Louise R Howe Journal: Cancer Prev Res (Phila) Date: 2008-08